



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

**Date:** May 15, 2009

**To:** Primary Clinical Research Associates

**From:** Linda S. Long  
Research Protocol Specialist III

**Re:** **N064B, Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma**

The Evaluation/Treatment Forms for both Arm A and Arm B have been revised as follows:

Form Title	Brief Description of Edit
Evaluation/Treatment Form (Arm A)	<p><b>Hold/Modified reasons updated as defined by section 8.0:</b></p> <ul style="list-style-type: none"> <li>Was this cycle of treatment held (<i>Day 1</i>)? - 7 additional reasons added</li> <li>Reason Modified (Erlotinib) - 1 reason deleted, Pulmonary/Upper Respiratory</li> <li>"Not BSA changes" deleted from "Erlotinib" row</li> </ul>
Evaluation/Treatment Form (Arm B)	<p><b>Hold/Modified reasons updated as defined by section 8.0:</b></p> <ul style="list-style-type: none"> <li>Was this cycle of treatment held (<i>Day 1</i>)? - 7 additional reasons added</li> <li>Reason Modified (Panitumumab) - 2 reasons deleted, Pulmonary/Upper Respiratory and Metabolic/Laboratory</li> <li>Reason Modified (Erlotinib) - 1 reason deleted, Pulmonary/Upper Respiratory</li> <li>"Not BSA changes" deleted from "Reason Modified" row for Panitumumab and Erlotinib</li> </ul>

The Booklet Order Form has also been updated as follows:

### **Registration Patient Questionnaire**

Number of booklets needed: \_\_\_\_\_

### **Follow-up Patient Questionnaire**

Number of booklets needed: \_\_\_\_\_

If you have any questions, please feel free to contact me.

Enclosure